A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile

BMC Infectious Diseases

Volumn 16, Issue 1, 2016, Pages

  Zhang, Bao Zhong ^a,b,c   Cai, Jianpiao ^b   Yu, Bin ^a   Hua, Yanhong ^a   Lau, Candy Choiyi ^b   Kao, Richard Yi Tsun Tsun ^b   Sze, Kong Hung ^b   Yuen, Kwok Yung ^b   Huang, Jian Dong ^a,c,d  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF HONG KONG   (China)

^d SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

Author keywords

Clostridium difficile; DNA vaccine; Toxin A (TcdA); Toxin B (TcdB)

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; BACTERIAL PROTEIN; BACTERIAL TOXIN; BACTERIAL VACCINE; DNA VACCINE; ENTEROTOXIN; TCDA PROTEIN, CLOSTRIDIUM DIFFICILE; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DISEASE SEVERITY; DNA IMMUNIZATION; DRUG RECEPTOR BINDING; FEMALE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PATHOGENESIS; PEPTOCLOSTRIDIUM DIFFICILE; ANIMAL; BAGG ALBINO MOUSE; COS CELL LINE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENETICS; IMMUNOLOGY; MESOCRICETUS; PATHOGENICITY; PLASMID;

ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; CLOSTRIDIUM DIFFICILE; COS CELLS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FEMALE; MESOCRICETUS; MICE, INBRED BALB C; PLASMIDS; VACCINES, DNA;

EID: 84992202444     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-016-1924-1     Document Type: Article

References (33)

1. Yannelli B, Gurevich I, Schoch PE, Cunha BA. Yield of stool cultures, ova and parasite tests, and Clostridium difficile determinations in nosocomial diarrheas. Am J Infect Control. 1988;16(6):246-9.
2. Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247-63.
3. Giannasca PJ, Warny M. Active and passive immunization against Clostridium difficile diarrhea and colitis. Vaccine. 2004;22(7):848-56.
4. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther. 2000;25(2):101-9.
5. Zhu Y, Wang L, Feng S, Wang S, Zheng C, Wang J, Du C, Feng Y, Li D, Shi Y, et al. Risk factors for Clostridium difficile-associated diarrhea among cancer patients. Zhonghua Zhong Liu Za Zhi Chinese J Oncol. 2014;36(10):773-7.
6. Kelly CP, LaMont JT. Clostridium difficile--more difficult than ever. N Engl J Med. 2008;359(18):1932-40.
7. Freeman J, Stott J, Baines SD, Fawley WN, Wilcox MH. Surveillance for resistance to metronidazole and vancomycin in genotypically distinct and UK epidemic Clostridium difficile isolates in a large teaching hospital. J Antimicrob Chemother. 2005;56(5):988-9.
8. Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in Clostridium difficile-associated disease: Past and present perspectives. Gut Microbes. 2010;1(1):58-64.
9. Dupuy B, Raffestin S, Matamouros S, Mani N, Popoff MR, Sonenshein AL. Regulation of toxin and bacteriocin gene expression in Clostridium by interchangeable RNA polymerase sigma factors. Mol Microbiol. 2006;60(4):1044-57.
10. Dupuy B, Govind R, Antunes A, Matamouros S. Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol. 2008;57(Pt 6):685-9.
11. Tan KS, Wee BY, Song KP. Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol. 2001;50(7):613-9.
12. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010;467(7316):711-3.
13. Barroso LA, Wang SZ, Phelps CJ, Johnson JL, Wilkins TD. Nucleotide sequence of Clostridium difficile toxin B gene. Nucleic Acids Res. 1990;18(13):4004.
14. Wren BW, Clayton CL, Tabaqchali S. Nucleotide sequence of Clostridium difficile toxin A gene fragment and detection of toxigenic strains by polymerase chain reaction. FEMS Microbiol Lett. 1990;58(1):1-6.
15. Baliban SM, Michael A, Shammassian B, Mudakha S, Khan AS, Cocklin S, Zentner I, Latimer BP, Bouillaut L, Hunter M, et al. An optimized, synthetic DNA vaccine encoding the toxin A and toxin B receptor binding domains of Clostridium difficile induces protective antibody responses in vivo. Infect Immun. 2014;82(10):4080-91.
16. Jin K, Wang S, Zhang C, Xiao Y, Lu S, Huang Z. Protective antibody responses against Clostridium difficile elicited by a DNA vaccine expressing the enzymatic domain of toxin B. Hum Vaccin Immunother. 2013;9(1):63-73.
17. Tian JH, Fuhrmann SR, Kluepfel-Stahl S, Carman RJ, Ellingsworth L, Flyer DC. A novel fusion protein containing the receptor binding domains of C. difficile toxin A and toxin B elicits protective immunity against lethal toxin and spore challenge in preclinical efficacy models. Vaccine. 2012;30(28):4249-58.
18. Siddiqui F, O'Connor JR, Nagaro K, Cheknis A, Sambol SP, Vedantam G, Gerding DN, Johnson S. Vaccination with parenteral toxoid B protects hamsters against lethal challenge with toxin A-negative, toxin B-positive clostridium difficile but does not prevent colonization. J Infect Dis. 2012;205(1):128-33.
19. Gardiner DF, Rosenberg T, Zaharatos J, Franco D, Ho DD. A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A. Vaccine. 2009;27(27):3598-604.
20. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun. 2006;74(11):6339-47.
21. Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342(6):390-7.
22. Marozsan AJ, Ma D, Nagashima KA, Kennedy BJ, Kang YK, Arrigale RR, Donovan GP, Magargal WW, Maddon PJ, Olson WC. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies. J Infect Dis. 2012;206(5):706-13.
23. Humphreys DP, Wilcox MH. Antibodies for treatment of Clostridium difficile infection. Clin Vaccine Immunol. 2014;21(7):913-23.
24. Ni Eidhin DB, O'Brien JB, McCabe MS, Athie-Morales V, Kelleher DP. Active immunization of hamsters against Clostridium difficile infection using surface-layer protein. FEMS Immunol Med Microbiol. 2008;52(2):207-18.
25. Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG. Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. BioTechniques. 1996;20(1):102. -104, 106, 108-110.
26. Leuzzi R, Spencer J, Buckley A, Brettoni C, Martinelli M, Tulli L, Marchi S, Luzzi E, Irvine J, Candlish D, et al. Protective efficacy induced by recombinant Clostridium difficile toxin fragments. Infect Immun. 2013;81(8):2851-60.
27. Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL. Molecular characterization of the Clostridium difficile toxin A gene. Infect Immun. 1990;58(2):480-8.
28. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G. Human Hypervirulent Clostridium difficile Strains Exhibit Increased Sporulation as Well as Robust Toxin Production. J Bacteriol. 2010;192(19):4904-11.
29. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985;47(2):349-52.
30. Drudy D, Fanning S, Kyne L. Toxin A-negative, toxin B-positive Clostridium difficile. Int J Infect Dis. 2007;11(1):5-10.
31. Drudy D, Harnedy N, Fanning S, Hannan M, Kyne L. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin B-positive Clostridium difficile. Infect Control Hospital Epidemiol. 2007;28(8):932-40.
32. Drudy D, Harnedy N, Fanning S, O'Mahony R, Kyne L. Isolation and characterisation of toxin A-negative, toxin B-positive Clostridium difficile in Dublin, Ireland. Clin Microbiol infect. 2007;13(3):298-304.
33. Frey SM, Wilkins TD. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun. 1992;60(6):2488-92.